Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for GNMLF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GNMLF and 80,000+ other tickers.
See exactly how GNMLF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GNMLF and 80,000+ other tickers.
Genomma Lab Internacional, S.A.B. de C.V., alongside its various operating units, specializes in the creation, promotion, and distribution of a wide array of over-the-counter (OTC) pharmaceutical goods and personal care items. Its operations span across Mexico and numerous international markets. The company's extensive product portfolio addresses diverse consumer needs, encompassing categories such as skincare, hair care, general health and wellness solutions, and pain management. Specific offerings include remedies for coughs and colds, digestive health aids, sexual well-being products…
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q2 2026 Earnings Call Transcript
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q1 2026 Earnings Call Transcript
MEXICO CITY, April 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter 2026.
MEXICO CITY, April 13, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its First Quarter 2026 Earnings Results on Wednesday, April 22, 2026, after the Mexican Stock Exchange (BMV) close.
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q4 2025 Earnings Call Transcript